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This thesis aimed to investigate several characteristic features of Parkinson’s disease 
(PD) and the impact of diet thereon, using different animal models. The investigated 
features included neuroinflammation, changes in the dopaminergic and purinergic 
system and alterations in microbiota and behavior. This thesis was divided in three 
parts. In the first part, the purinergic system was reviewed (Chapter 2) and investigated 
in a zebrafish model for PD (Chapter 3). The second part addressed the feasibility of 
Positron Emission Tomography (PET) imaging in adult zebrafish (Chapter 4). In the 
third part, the effect of a high-fat diet was studied in healthy rats (Chapter 5) and a rat 
model for PD (Chapter 6 and 7). This chapter briefly discusses the relation between 
the results described in this thesis and the future perspectives in basic science and 
clinical research. 
 
Treatment for Parkinson’s disease 
 
PD is a common neurodegenerative disorder that lacks proper treatment without side 
effects. Our limited understanding of the basic mechanisms of the disease before the 
onset of disease symptoms and the late diagnosis complicate the development of a 
curative treatment. The investigation of drug targets, or even completely new 
pathways, that differentiate from the classical dopaminergic approach should 
contribute to the identification of new biomarkers for early diagnosis and therapeutic 
interventions. 
One of these approaches could be the investigation of the purinergic system, 
which is already being explored as a potential target for pharmacological and non-
pharmacological treatment of PD. At present, one drug targeting the purinergic system 
has already been approved as add-on treatment for PD: the selective adenosine A2A 
receptor antagonist istradefylline. This drug was approved based on results of different 
clinical trials with more than 4000 patients in total. In general, these trials showed a 
decrease in daily off symptoms, which occur when levodopa is not working well, in 
istradefylline treated PD patients, as compared to placebo treated patients (Chen & 
Cunha, 2020). Other drugs targeting the adenosine A2A receptor, like preladenant, 
vipadenant and caffeine, have been tested as treatment for PD, however overall results 
were disappointing (Nazario, da Silva, & Bonan, 2017; Zhou et al., 2017). The influence 
of adenosine on the dopaminergic system and the success of istradefylline still support 
the search for purinergic receptor-targeting drugs (receptor antagonists), since 
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adenosine is capable of negatively modulating dopamine receptors through direct and 
indirect pathways (Tóth, Antal, Bereczki, & Sperlágh, 2019). Another strategy would 
be to target both the adenosine and the dopamine systems by a drug that is able to 
simultaneously bind to A2A and D2 receptors. Such a bispecific drug would have 
increased specificity, since the drug will only act on specific heterodimers. As a result, 
this could lead to a reduction in the dose needed and, consequently, the side effects 
(Soriano et al., 2009). This approach has been investigated for a long time, but only 
recently a dual targeted drug from the class of indolylpiperazinylpyrimidines was shown 
to have promising in vitro and in vivo results (Shao et al., 2018; Soriano et al., 2009). 
Problems related to the size of the molecule and the fast dissociation from the receptor 
heterodimer are still a challenge in this field (Carli et al., 2017).  
Non-pharmacological approaches in the treatment of PD are usually related to 
the improvement of quality of life of patients through interventions like physical activity, 
diet, music therapy, and acupuncture (Ahn, Chen, Bredow, Cheung, & Yu, 2017). In 
animal studies, physical exercise was shown to induce a reduction in adenosine 
receptor expression, reinforcing the idea that the neuroprotective effect of physical 
activity is probably through a reduction of the antagonistic effect of adenosine on 
dopamine signalling (Clark et al., 2014). Diet is already known to have an impact on 
neuroprotection and neurodegeneration (Bianchi, Herrera, & Laura, 2019). Different 
types of diet can reduce or accelerate the progression of PD (Seidl, Santiago, Bilyk, & 
Potashkin, 2014). The beneficial effects of nutrients, like vitamins and antioxidants, on 
neuroinflammation was also found (Kurtys et al., 2019, 2018).   
Additional efforts to find new drugs or new ways to slowdown the progression 
of PD are necessary to improve the quality of life for PD patients. Taking in 
consideration that a purinergic drug and lifestyle intervention can modulate disease 
progression and/or symptoms, it is important to explore the specific underlying 
mechanisms. This could help shedding some light on the pathways that are 
responsible for the onset of the disease and the course of disease progression before 
the diagnosis of patients.  
 
Zebrafish as a model in basic PD research 
 
There are different methodologies to investigate a disease. The most frequently used 
are observational research with or without the collection of biological samples in 
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humans, intervention studies and mimicking (part of the) disease symptoms in animal 
models. One of these animal models is the zebrafish. Zebrafish can be easily 
maintained in the laboratory and the production of large amounts of eggs can be 
induced in all periods of the year. This animal also has all major organs that are present 
in vertebrates, like the heart, eyes, kidneys, intestines, brain and pancreas. Moreover, 
zebrafish also have most of the neurotransmission systems that are present in rodents 
and primates (Rahman Khan & Sulaiman Alhewairini, 2019). About 80% of the genes 
related with human disease have an equivalent in zebrafish, which offers the 
opportunity to target specific disease-related genes, turn them on or off, or introduce 
foreign genes (Howe et al., 2013).  
Because of these and other characteristics, zebrafish have already become an 
important animal model in basic research, in which they are mainly used to unravel 
disease mechanisms and to discover new potential targets for treatment. In Chapter 
3, we translated the well-known 6-hydroxydopamine (6-OHDA) brain injection model 
of PD from rodents to the zebrafish. This procedure is challenging because of the size 
of the animal and the fact that it needs to be fast (the injection is done with the animal 
under stereomicroscope being just rinsed on the gills), but it can be reproduced. This 
model showed behavioural changes at various time points and there is a dose-
dependent relation between 6-OHDA exposure and the features of PD. Our results 
showed that 6-OHDA injection in zebrafish caused an increase in dopamine D2 
receptor expression, while the adenosine A2A receptor density initially was not affected 
by 6-OHDA, but decreased over time in 6-OHDA-treated animals. It has previously 
been described that adenosine and dopamine receptors are connected because they 
can form heterodimers (A2A/D2) in other species (Beggiato et al., 2014; Ferré & Ciruela, 
2019). However, in zebrafish this is not known yet. For a more comprehensive 
understanding of chapter 3 findings, quantification of D2 and A2A receptor protein 
levels, availability and functionality of these receptors and elucidation of their status of 
heterodimerization should be investigated in order to identify if both receptors are 
similarly affected by 6-OHDA in zebrafish as in rodents (Antonelli et al., 2006; 
Fernández-Dueñas et al., 2015; Zhou et al., 2017). Enzymatic activity involved in the 
control of adenosine levels on extracellular medium can be easily investigated in 
zebrafish, as these enzymes are already used to investigate purinergic signalling in 
several pathological conditions (Altenhofen et al., 2018; Capiotti et al., 2016). In 
addition, pharmacological modulation of the zebrafish model of PD with purinergic 
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antagonists and agonists could provide more insight in the complex interaction 
between the purinergic system and other neurotransmitter systems, like the 
cholinergic, glutamatergic, GABAergic, cannabinergic and serotoninergic systems 
(Burnstock, 2008; Moreno et al., 2018; Ribeiro, Cunha, Correia-de-Sa, & Sebastiao, 
1996; Tóth et al., 2019). These would give a better overview of all the factors that are 
involved in the degeneration of the dopaminergic system and may provide some hints 
for new therapeutic targets.  
 
PET imaging of Zebrafish  
 
PET is a versatile technique for studying biochemical and physiological processes in 
living organisms. So far, PET has mainly been applied in relatively large species like 
humans, non-human primates and rodents, as the application can be challenging in 
smaller animal models. Some studies report the use of nuclear imaging techniques in 
zebrafish, but only in dead animals or without recovery from anaesthesia (Bufkin, 2015; 
Dorsemans et al., 2017; Henderson et al., 2019). Efforts to establish truly in vivo PET 
imaging in zebrafish has not been published yet. In this thesis, we  investigated the 
feasibility to perform PET experiments with living adult zebrafish (Chapter 4). The first 
challenge faced during the establishment of a procedure to obtain PET images was 
related to the concern of the use of a liquid in PET scanners, which was solved by 
ceiling the falcon tube contain the zebrafish with parafilm. The second challenge was 
to have sufficient time to capture images and keep the animals alive under 
anaesthesia. For this purpose, different concentrations of anaesthetic were tested. The 
third challenge was the impossibility to use a recirculating water system as this would 
cause movement of the fish and thus blurring of the images. The fourth challenge was 
to keep the water on an acceptable temperature for animals. To overcome the 
challenges, the technical training of researchers was essential in order to complete the 
procedure quick and efficiently. In this thesis we demonstrated that PET imaging in 
living zebrafish is possible. This zebrafish model could be complimentary to the models 
in rodents and in vitro analyses. Zebrafish can be used as an avatar, CRISPR and 
mutants, and considered as a tool to optimize, for example, a therapy dose for patients 
and predict tumour response (Costa et al., 2020). 
In this thesis, the experiments were performed by the same researcher, but with 
training and more standardization this technique could be disseminated to other PET 
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centres as well. To implement this technique at different sites, my goal for the next 
years is to invest in the development of this field by establishing worldwide 
collaborations.  
The development of new drugs and diagnostics can benefit from the 
combination of high-resolution PET/CT and PET/MRI with the zebrafish model. The 
main benefits are a fast throughput, since multiple zebrafish can be imaged at the same 
time with only a small amount of radiotracer, and a relatively low cost for breeding and 
maintaining of the animals. Unfortunately, we can only use the zebrafish in the adult 
stage when the size reaches around 3-4 cm, because of the resolution of the current 
PET cameras (0.7 - 1.5 mm). The small amount of blood in adult zebrafish and the 
limited time of anaesthesia will preclude kinetic modelling studies and the collection of 
multiple blood samples to perform metabolites analysis. On the other hand, the small 
size is an advantage, since the whole body of the animal can be scanned and therefore 
the overall distribution of the tracer is clear.  
Another possibility that can be implemented in the field of molecular imaging is 
the use of zebrafish larvae (until five days post fertilization). Larvae can be incubated 
with the tracer and accumulated radioactivity can be detected with equipment such as 
a gamma counter or autoradiography. Thus, zebrafish larvae could fill the gap between 
cell studies and in vivo imaging studies. This approach can be used for binding studies, 
to measure specific binding of the tracer using various antagonists or agonists that 
compete with it. The advantage of using larvae until five days after fertilization is that 
they are not considered to be experimental animals yet, according to Central Authority 
for Scientific Procedures on Animal application in the Netherlands (not all the countries 
have the same legislation) and thus lengthy administrative procedures to obtain 
approval for the studies is not required. Moreover, the independent feeding of the 
larvae (yolk supplies) reduces the time and the costs of research even more. In this 
stage of life, the larvae have already developed all the organs and neurotransmitter 
systems, thus could be an add value from the studies with cells. One example is the 
use of zebrafish larvae as an avatar for studies with radiotherapy. In an article by Costa 
and colleagues, zebrafish were used as a tool to optimize the therapeutic dose for 
patients and predict tumour response. The zebrafish larvae were injected with 
colorectal cancer cells from biopsies of patients and different radiation doses were 
applied (Costa et al., 2020).   
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Because of the challenges associated with PET imaging in zebrafish, 
concerning the need to obtain a new license from the Central Authority for Scientific 
Procedures on Animals to perform these experiments and the limited amount of time 
to complete this PhD thesis, the final experiments in this thesis were performed in rats. 
 
The effect of diet on the dopaminergic system and its impact on Parkinson’s disease 
 
Diet influences different processes in the body: satiety, pleasure, reward and 
necessity, among others. The role of food has expanded with human evolution, as 
nowadays food also plays a critical role in societal status (Luca, Perry, & Di Rienzo, 
2010). The type of diet also changed with evolution, as the availability of an “easy meal” 
has increased the consumption of fast food over the world (De Vogli, Kouvonen, & 
Gimeno, 2014). The reward system does not only have an important role in the 
modulation of what we eat and how much we eat, but is also associated with addiction, 
motivation and mood disorders (Arias-Carrián, Stamelou, Murillo-Rodríguez, 
Menéndez-Gonzlez, & Pöppel, 2010). The excessive consumption of highly palatable 
food and the disbalance of the reward system can cause obesity (Kenny, 2011). The 
consumption habits of the Western society, culminating in a so-called the Western diet, 
have resulted in an increase in the number of diabetic patients. For research purposes, 
the Western diet can be translated to animals and is referred to as the cafeteria diet, 
consisting of highly palatable food (with high concentrations of sugar) and high fat chow 
(Lutz & Woods, 2012). With this diet, dopamine release is increased chronically and 
causes addictive behaviour, similar to what is observed in drugs abuse (Macedo, 
Freitas, & Torres, 2016). Because of the potentially detrimental impact of bad eating 
habits on society, it is important to know the processes that are affected by the Western 
diet, so that we can understand how diet can influence the development of diseases 
like diabetes. Such knowledge could also help in the development of new 
pharmacological strategies. In our longitudinal study described in Chapter 5, the effect 
of a cafetaria diet on the dopaminergic system was investigated. The observed 
decrease of dopamine D2 receptor availability after cafeteria diet could be the result of 
a diet-induced increase in dopamine release or a decrease in expression of the D2 
receptor. The challenge with highly palatable food, which was expected to result in a 
blunted dopamine response in those animals that were exposed to the cafeteria diet, 
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did not show any effect. Possibly the timing of the PET scan or the intensity of the 
challenge was not adequate to observe any effect of the challenge.   
After investigation of the effects of a cafeteria diet on dopamine D2 receptor 
availability in healthy animals, research was continued by exposing an animal model 
of PD to a high-fat diet, to mimic the effects of a bad lifestyle on a number of PD disease 
characteristics (Chapter 6 and 7). Diet is hypothesized to influence the onset and 
progression of PD (Seidl et al., 2014). 11C-raclopride and 11C-PBR28 PET scans were 
performed to investigate the effect of diet on the dopaminergic system and on 
neuroinflammation, respectively, in the 6-OHDA model of PD. Imaging results were 
correlated with behavioural parameters and changes in microbiota. Overall, the results 
demonstrated a detrimental role of the high-fat diet on the severity of dopaminergic 
abnormalities and neuroinflammation. These effects could have been triggered by the 
observed changes in gut microbiota. Fortunately, diet is an easily modifiable risk factor. 
If prospective patients modify their eating habits and stop overeating, not only obesity 
could be prevented, but also the onset and progression of PD could be delayed or even 
prevented. However, this will not be easy, as many PD patients are suffering from 
depression, anxiety and other stressful situations that can lead to an overeating 
pattern. Understanding the basic mechanisms of the effects of diet in these patients 
can help in disease management. An interesting observation in our study was the 
correlation between changes in microbiota and glial activation in the brain. In the future, 
it may become possible to identify different types of disease just from the microbiota 
composition or from certain bacteria. If so, screening programs for the early 
identification of high-risk subjects could be started. This would enable preventive 
intervention. Nowadays, it is still difficult identify such early biomarkers due to the lack 
of standardization across the studies. For better results, large cohort studies with a 
diverse ethnic profile and standard protocols are necessary (Lavelle & Hill, 2019). 
Perhaps the LifeLines cohort in Groningen could provide the required data for the 
identification of predictive microbiota signatures. 
The link between neurodegenerative disorders and diabetes type 2, or a pre-
diabetic state, supports the hypothesis that treatments for diabetes, like metformin and 
glucagon-like peptide 1 (GLP-1), may also be applied in patients with 
neurodegenerative disease (Elbassuoni & Ahmed, 2019; Paudel, Angelopoulou, 
Piperi, Shaikh, & Othman, 2020). The mechanisms of action of metformin are related 
to the balance between survival and death in cells, signalling pathways that are also 
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connected to neurodegenerative diseases (Rotermund, Machetanz, & Fitzgerald, 
2018). Animal studies report that metformin and GLP-1 are capable of reducing 
disease severity in animal models of PD (Bayliss et al., 2016; Lu et al., 2016; Patil, 
Jain, Ghumatkar, Tambe, & Sathaye, 2014; Zhang, Zhang, Li, & Hölscher, 2018). 
There is not enough data from clinical studies to conclude if metformin can be used as 
an treatment against PD (Paudel et al., 2020). However, the daily subcutaneous 
injection of GLP-1 was shown to have positive effects on motor and non-motor 
symptoms in PD patients, that did not persist after treatment was stopped (Athauda & 
Foltynie, 2016; Athauda et al., 2018).  
To elucidate the effect of diet on the purinergic system of PD patients, PET 
studies with tracers like 11C-preladenant, targeting the adenosine A2A receptor, would 
be extremely interesting. The purinergic system is involved in different pathways 
related to inflammation, insulin resistance, hypothalamic control of feeding and control 
of white and brown adipocytes that directly affect obesity (Burnstock & Gentile, 2018). 
Such studies could help the development of an intervention with an A2A antagonist that 
could benefit PD patients. Future PET studies with tracers such as 11C-raclopride, 11C-
PBR28 and 11C-preladenant in PD patients with different lifestyles can help clarifying 
the involvement and interrelationship of these system in PD. These PET studies can 
be combined with, amongst others, studying microbiota, cytokine and a-synuclein 




The world’s obese population is increasing and so are the associated comorbidities. A 
link between obesity and neurodegenerative diseases has already been found. The 
search for knowledge about the basic pathways involved and potential interventions 
based on changes in lifestyle can help to prevent or delay neurodegenerative diseases. 
Increased understanding of the early disease stages could also facilitate the 
development of new treatments and diagnostic tools. My contribution to this field 
included investigating the relation between obesity and PD in an animal model in 
longitudinal studies, using PET. This PET approach enabled the combination of 
studying behaviour, microbiota, dopaminergic and purinergic response, and 
(neuro)inflammation. In addition, my work opened the possibility to investigate 
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